Printer Friendly

ORTHOLOGIC CORP. REPORTS FINANCIAL RESULTS FOR SECOND QUARTER, FIRST SIX MONTHS 1993

 PHOENIX, Ariz., July 12 /PRNewswire/ -- OrthoLogic (NASDAQ-NMS: OLGC), a developer of technologically advanced orthopaedic trauma products, today reported a second quarter 1993 loss of $795,229 or $.12 per share, compared to a loss of $801,243 or $.21 per share for the same 1992 quarter.
 Sales of OrthoLogic's first commercial product, the OrthoFrame(TM) external fixation device, totaled $69,877 for the second quarter 1993. There were no sales for the same 1992 quarter. The company also reported grant revenue of $16,667 for the second quarter 1993 compared to zero for the second quarter 1992.
 "The shipment and sale of OrthoFrame, two months earlier than originally projected, marks the commencement of commercial revenue- generating activities for the company," said Allan M. Weinstein, Ph.D., president and chief executive officer of OrthoLogic. "It broadens our presence in the orthopaedic community and leads the way for the introduction of other products currently being developed."
 Operating expenses for the second quarter 1993 were $935,189 which was an increase of 19 percent over the same 1992 quarter. This is because of increased research and development activities and increased clinical and regulatory costs.
 Research and development expenses in 1993 include development costs associated with the OrthoFrame device. Clinical and regulatory costs increased as a result of the commencement of clinical trials in February 1993 on the company's SpinaLogic(TM) 1000 product, a portable, noninvasive bone growth stimulator. This device is designed as an adjunctive post-surgical treatment to enhance healing for patients who undergo spinal fusion procedures.
 For the six months ended June 30, 1993, the net loss was $1,580,777 or $.25 per share, compared to a loss of $1,592,868 or $.43 per share for the same 1992 period.
 OrthoLogic is a developer of technologically advanced orthopaedic trauma products that enhance healing of musculoskeletal tissues. The company, founded in 1987, completed its initial public offering (IPO) in January 1993, and is headquartered in Phoenix.
 -0- 7/12/93
 /CONTACT: Allan M. Weinstein, president and CEO of OrthoLogic, 602-437-5520/
 (OLGC)


CO: OrthoLogic Corp. ST: Arizona IN: MTC SU:

EH -- LA009 -- 0342 07/12/93 10:42 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 12, 1993
Words:357
Previous Article:CASINO TO EXPLORE SALE OF SMART & FINAL INC.
Next Article:GAMING CORPORATION OF AMERICA ANNOUNCED GOLDEN NICKEL'S COMMENCEMENT OF REVENUE SHARING AT WISCONSIN DELLS AREA CASINO
Topics:


Related Articles
ORTHOLOGIC ANNOUNCES FIRST QUARTER 1993 FINANCIAL RESULTS
FIRST NATIONWIDE REPORTS SECOND-QUARTER RESULTS
ORTHOLOGIC CORP. REPORTS THIRD QUARTER FINANCIAL RESULTS AND RESTRUCTURING OF ITS DISTRIBUTION
ORTHOLOGIC ANNOUNCES PRODUCT DISTRIBUTION AGREEMENTS
ORTHOLOGIC REPORTS FINANCIAL RESULTS FOR FOURTH QUARTER AND YEAR ENDED DEC. 31, 1993
ORTHOLOGIC FOURTH QUARTER SALES INCREASE 47.1 PERCENT FROM PRIOR QUARTER; SALES REACH $5.0 MILLION FOR FISCAL 1994
OrthoLogic Reports Second Quarter Results
OrthoLogic Settles Legal Dispute
OrthoLogic Reports Third Quarter Results.
OrthoLogic Reports Fourth Quarter and Full-Year 2005 Results.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters